Key clinical point: Reduced symptom severity and use of budesonide orodispersible tablets and high topical corticosteroid (tC) doses (eg, fluticasone propionate metered dose ≥ 1 mg/day from inhalation devices) are all independent predictors of tC effectiveness in patients with eosinophilic esophagitis (EoE) in the real‐world setting.

Major finding: Corticosteroid treatment proved to be the most important determining factor in achieving clinico-histological remission, with budesonide orodispersible tablets presenting the highest efficacy (adjusted odds ratio [aOR], 18.9; P < .001). High tC doses (aOR, 4.3; P = .03) and lower symptom scores (aOR, 0.9; P = .01) were also significant predictors of tC effectiveness.

Study details: This real-world cross‐sectional analysis of the multicenter EoE CONNECT registry assessed the data on 1456 prescriptions of tC monotherapy used in 866 patients with EoE.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Laserna‐Mendieta EJ, Navarro P, Casabona-Francés S, et al. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry. United European Gastroenterol J. Published online January 29, 2024. Source

Key clinical point: Reduced symptom severity and use of budesonide orodispersible tablets and high topical corticosteroid (tC) doses (eg, fluticasone propionate metered dose ≥ 1 mg/day from inhalation devices) are all independent predictors of tC effectiveness in patients with eosinophilic esophagitis (EoE) in the real‐world setting.

Major finding: Corticosteroid treatment proved to be the most important determining factor in achieving clinico-histological remission, with budesonide orodispersible tablets presenting the highest efficacy (adjusted odds ratio [aOR], 18.9; P < .001). High tC doses (aOR, 4.3; P = .03) and lower symptom scores (aOR, 0.9; P = .01) were also significant predictors of tC effectiveness.

Study details: This real-world cross‐sectional analysis of the multicenter EoE CONNECT registry assessed the data on 1456 prescriptions of tC monotherapy used in 866 patients with EoE.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Laserna‐Mendieta EJ, Navarro P, Casabona-Francés S, et al. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry. United European Gastroenterol J. Published online January 29, 2024. Source

Key clinical point: Reduced symptom severity and use of budesonide orodispersible tablets and high topical corticosteroid (tC) doses (eg, fluticasone propionate metered dose ≥ 1 mg/day from inhalation devices) are all independent predictors of tC effectiveness in patients with eosinophilic esophagitis (EoE) in the real‐world setting.

Major finding: Corticosteroid treatment proved to be the most important determining factor in achieving clinico-histological remission, with budesonide orodispersible tablets presenting the highest efficacy (adjusted odds ratio [aOR], 18.9; P < .001). High tC doses (aOR, 4.3; P = .03) and lower symptom scores (aOR, 0.9; P = .01) were also significant predictors of tC effectiveness.

Study details: This real-world cross‐sectional analysis of the multicenter EoE CONNECT registry assessed the data on 1456 prescriptions of tC monotherapy used in 866 patients with EoE.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Laserna‐Mendieta EJ, Navarro P, Casabona-Francés S, et al. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry. United European Gastroenterol J. Published online January 29, 2024. Source

Key clinical point: Children with eosinophilic esophagitis (EoE) have distinct salivary immunoinflammatory protein profiles compared with those without EoE, highlighting the diagnostic potential of salivary proteins in pediatric EoE.

Major finding: Children with EoE were distinguished from those without EoE through a panel of 10 proteins (higher expression levels of C-C motif chemokine-3, macrophage metalloelastase, granulocyte colony-stimulating factor-3, interleukin [IL]-15, pro-transforming growth factor alpha, and oncostatin-M and lower expression levels of IL-18, C-C motif chemokine-2, interstitial collagenase, and macrophage colony-stimulating factor-1), with an accuracy of 0.95 validated through the Least Absolute Shrinkage and Selection Operator regression.

Study details: This cross-sectional study analyzed the saliva samples collected from 40 children aged 6-18 years with (n = 23) or without EoE (n = 17) immediately before their scheduled esophagogastroduodenoscopy with biopsies.

Disclosures: Girish Hiremath and Seesandra V Rajagopala were supported by grants from the US National Institutes of Health. The former declared serving as a consultant for and receiving speaker fees from various organizations.

Source: Hiremath G, Wang Y, Correa H, Sheng Q, Rajagopala SV. Salivary immunoinflammatory proteins identify children with eosinophilic esophagitis. Allergy. 2024 (Jan 29). doi: 10.1111/all.16040 Source

Key clinical point: Children with eosinophilic esophagitis (EoE) have distinct salivary immunoinflammatory protein profiles compared with those without EoE, highlighting the diagnostic potential of salivary proteins in pediatric EoE.

Major finding: Children with EoE were distinguished from those without EoE through a panel of 10 proteins (higher expression levels of C-C motif chemokine-3, macrophage metalloelastase, granulocyte colony-stimulating factor-3, interleukin [IL]-15, pro-transforming growth factor alpha, and oncostatin-M and lower expression levels of IL-18, C-C motif chemokine-2, interstitial collagenase, and macrophage colony-stimulating factor-1), with an accuracy of 0.95 validated through the Least Absolute Shrinkage and Selection Operator regression.

Study details: This cross-sectional study analyzed the saliva samples collected from 40 children aged 6-18 years with (n = 23) or without EoE (n = 17) immediately before their scheduled esophagogastroduodenoscopy with biopsies.

Disclosures: Girish Hiremath and Seesandra V Rajagopala were supported by grants from the US National Institutes of Health. The former declared serving as a consultant for and receiving speaker fees from various organizations.

Source: Hiremath G, Wang Y, Correa H, Sheng Q, Rajagopala SV. Salivary immunoinflammatory proteins identify children with eosinophilic esophagitis. Allergy. 2024 (Jan 29). doi: 10.1111/all.16040 Source

Key clinical point: Children with eosinophilic esophagitis (EoE) have distinct salivary immunoinflammatory protein profiles compared with those without EoE, highlighting the diagnostic potential of salivary proteins in pediatric EoE.

Major finding: Children with EoE were distinguished from those without EoE through a panel of 10 proteins (higher expression levels of C-C motif chemokine-3, macrophage metalloelastase, granulocyte colony-stimulating factor-3, interleukin [IL]-15, pro-transforming growth factor alpha, and oncostatin-M and lower expression levels of IL-18, C-C motif chemokine-2, interstitial collagenase, and macrophage colony-stimulating factor-1), with an accuracy of 0.95 validated through the Least Absolute Shrinkage and Selection Operator regression.

Study details: This cross-sectional study analyzed the saliva samples collected from 40 children aged 6-18 years with (n = 23) or without EoE (n = 17) immediately before their scheduled esophagogastroduodenoscopy with biopsies.

Disclosures: Girish Hiremath and Seesandra V Rajagopala were supported by grants from the US National Institutes of Health. The former declared serving as a consultant for and receiving speaker fees from various organizations.

Source: Hiremath G, Wang Y, Correa H, Sheng Q, Rajagopala SV. Salivary immunoinflammatory proteins identify children with eosinophilic esophagitis. Allergy. 2024 (Jan 29). doi: 10.1111/all.16040 Source

Key clinical point: Altered eating behaviors, including increased chewing and increased consumption time, observed in children with eosinophilic esophagitis (EoE) correlated with patient-reported symptoms, endoscopic findings, and histologic features.

Major finding: Children with vs without EoE demonstrated more chews per bite and increased consumption time with soft solid (P = .031 and P = .002, respectively), chewable (P = .047 and P = .005, respectively), and hard solid (P = .037 and P = .034, respectively) foods. Increased consumption time significantly correlated with a peak eosinophil count (r 0.42; P = .050) and decreased esophageal distensibility (r −0.82; P < .0001).

Study details: This prospective observational study included 27 children with EoE (age 5-17 years) and 25 control children without EoE who consumed four food items, each representing a different texture (puree, soft solid, chewable, and hard solid).

Disclosures: This study was supported by the 2021 American College of Gastroenterology Clinical Research Award and other sources. The authors declared no conflicts of interest.

Source: Kennedy KV, Umeweni CN, Alston M, et al. Esophageal remodeling correlates with eating behaviors in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2024 (Jan 18). doi: 10.14309/ajg.0000000000002661 Source

Key clinical point: Altered eating behaviors, including increased chewing and increased consumption time, observed in children with eosinophilic esophagitis (EoE) correlated with patient-reported symptoms, endoscopic findings, and histologic features.

Major finding: Children with vs without EoE demonstrated more chews per bite and increased consumption time with soft solid (P = .031 and P = .002, respectively), chewable (P = .047 and P = .005, respectively), and hard solid (P = .037 and P = .034, respectively) foods. Increased consumption time significantly correlated with a peak eosinophil count (r 0.42; P = .050) and decreased esophageal distensibility (r −0.82; P < .0001).

Study details: This prospective observational study included 27 children with EoE (age 5-17 years) and 25 control children without EoE who consumed four food items, each representing a different texture (puree, soft solid, chewable, and hard solid).

Disclosures: This study was supported by the 2021 American College of Gastroenterology Clinical Research Award and other sources. The authors declared no conflicts of interest.

Source: Kennedy KV, Umeweni CN, Alston M, et al. Esophageal remodeling correlates with eating behaviors in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2024 (Jan 18). doi: 10.14309/ajg.0000000000002661 Source

Key clinical point: Altered eating behaviors, including increased chewing and increased consumption time, observed in children with eosinophilic esophagitis (EoE) correlated with patient-reported symptoms, endoscopic findings, and histologic features.

Major finding: Children with vs without EoE demonstrated more chews per bite and increased consumption time with soft solid (P = .031 and P = .002, respectively), chewable (P = .047 and P = .005, respectively), and hard solid (P = .037 and P = .034, respectively) foods. Increased consumption time significantly correlated with a peak eosinophil count (r 0.42; P = .050) and decreased esophageal distensibility (r −0.82; P < .0001).

Study details: This prospective observational study included 27 children with EoE (age 5-17 years) and 25 control children without EoE who consumed four food items, each representing a different texture (puree, soft solid, chewable, and hard solid).

Disclosures: This study was supported by the 2021 American College of Gastroenterology Clinical Research Award and other sources. The authors declared no conflicts of interest.

Source: Kennedy KV, Umeweni CN, Alston M, et al. Esophageal remodeling correlates with eating behaviors in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2024 (Jan 18). doi: 10.14309/ajg.0000000000002661 Source

Key clinical point: Eosinophilic esophagitis (EoE) can be distinguished from eosinophilia caused by inflammatory bowel diseases (IBD) by measuring the expression levels of the major basic protein (MBP) biomarker.

Major finding: The median MBP staining levels were significantly higher in patients with EoE vs those with IBD-associated eosinophilia (52.8 vs 0.2; P < .001). Based on the MBP cutoff point of 3.49 units that distinguished EoE from non-EoE cases, 100% of patients with EoE were MBP positive compared with 3% of patients with IBD-associated eosinophilia (P < .05).

Study details: This retrospective study included 29 patients with EoE, 27 patients with both EoE and IBD, 29 patients with IBD-associated eosinophilia, 30 patients with IBD, and 30 control individuals without either EoE or IBD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Butzke S, Nasiri-Blomgren S, Corao-Uribe D, He Z, Molle-Rios Z. Major basic protein is a useful marker to distinguish eosinophilic esophagitis from IBD-associated eosinophilia in children. J Pediatr Gastroenterol Nutr. 2024 (Feb 5). doi: 10.1002/jpn3.12143 Source

Key clinical point: Eosinophilic esophagitis (EoE) can be distinguished from eosinophilia caused by inflammatory bowel diseases (IBD) by measuring the expression levels of the major basic protein (MBP) biomarker.

Major finding: The median MBP staining levels were significantly higher in patients with EoE vs those with IBD-associated eosinophilia (52.8 vs 0.2; P < .001). Based on the MBP cutoff point of 3.49 units that distinguished EoE from non-EoE cases, 100% of patients with EoE were MBP positive compared with 3% of patients with IBD-associated eosinophilia (P < .05).

Study details: This retrospective study included 29 patients with EoE, 27 patients with both EoE and IBD, 29 patients with IBD-associated eosinophilia, 30 patients with IBD, and 30 control individuals without either EoE or IBD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Butzke S, Nasiri-Blomgren S, Corao-Uribe D, He Z, Molle-Rios Z. Major basic protein is a useful marker to distinguish eosinophilic esophagitis from IBD-associated eosinophilia in children. J Pediatr Gastroenterol Nutr. 2024 (Feb 5). doi: 10.1002/jpn3.12143 Source

Key clinical point: Eosinophilic esophagitis (EoE) can be distinguished from eosinophilia caused by inflammatory bowel diseases (IBD) by measuring the expression levels of the major basic protein (MBP) biomarker.

Major finding: The median MBP staining levels were significantly higher in patients with EoE vs those with IBD-associated eosinophilia (52.8 vs 0.2; P < .001). Based on the MBP cutoff point of 3.49 units that distinguished EoE from non-EoE cases, 100% of patients with EoE were MBP positive compared with 3% of patients with IBD-associated eosinophilia (P < .05).

Study details: This retrospective study included 29 patients with EoE, 27 patients with both EoE and IBD, 29 patients with IBD-associated eosinophilia, 30 patients with IBD, and 30 control individuals without either EoE or IBD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Butzke S, Nasiri-Blomgren S, Corao-Uribe D, He Z, Molle-Rios Z. Major basic protein is a useful marker to distinguish eosinophilic esophagitis from IBD-associated eosinophilia in children. J Pediatr Gastroenterol Nutr. 2024 (Feb 5). doi: 10.1002/jpn3.12143 Source

Key clinical point: Pediatric patients with a more recent diagnosis of eosinophilic esophagitis (EoE) are likely to have a greater psychosocial burden from their condition, with a higher symptom burden score correlating positively with somatic symptom scores and negatively with quality of life (QoL).

Major finding: Compared with patients with longer disease duration (>12 months), those with shorter disease duration (6-12 months) had higher symptom burden (P = .03), somatic symptom (P < .01), and trait anxiety (P < .01) scores. Furthermore, a higher symptom burden was significantly associated with increased somatic symptoms (adjusted β [aβ] 0.34; 95% CI 0.23-0.45) and decreased QoL (aβ −0.42; 95% CI −0.59 to −0.25).

Study details: Findings are from a cross-sectional study including 87 pediatric patients with EoE, of whom 71 patients had longer disease duration.

Disclosures: This study was supported by a grant from the University of California San Diego (USCD) Academic Senate and US National Institutes of Health K24 and partially supported by the UCSD Altman Clinical and Translational Research Institute (ACTRI). The authors declared no conflicts of interest.

Source: Jensen ET, Chaiboonma K, Ayala O, Proia A, Aceves SS. Sleep, anxiety, somatization, quality of life, and resilience in pediatric patients with eosinophilic esophagitis. Clin Transl Gastroenterol. 2024 (Jan 11). Doi: 10.14309/ctg.0000000000000672  Source

Key clinical point: Pediatric patients with a more recent diagnosis of eosinophilic esophagitis (EoE) are likely to have a greater psychosocial burden from their condition, with a higher symptom burden score correlating positively with somatic symptom scores and negatively with quality of life (QoL).

Major finding: Compared with patients with longer disease duration (>12 months), those with shorter disease duration (6-12 months) had higher symptom burden (P = .03), somatic symptom (P < .01), and trait anxiety (P < .01) scores. Furthermore, a higher symptom burden was significantly associated with increased somatic symptoms (adjusted β [aβ] 0.34; 95% CI 0.23-0.45) and decreased QoL (aβ −0.42; 95% CI −0.59 to −0.25).

Study details: Findings are from a cross-sectional study including 87 pediatric patients with EoE, of whom 71 patients had longer disease duration.

Disclosures: This study was supported by a grant from the University of California San Diego (USCD) Academic Senate and US National Institutes of Health K24 and partially supported by the UCSD Altman Clinical and Translational Research Institute (ACTRI). The authors declared no conflicts of interest.

Source: Jensen ET, Chaiboonma K, Ayala O, Proia A, Aceves SS. Sleep, anxiety, somatization, quality of life, and resilience in pediatric patients with eosinophilic esophagitis. Clin Transl Gastroenterol. 2024 (Jan 11). Doi: 10.14309/ctg.0000000000000672  Source

Key clinical point: Pediatric patients with a more recent diagnosis of eosinophilic esophagitis (EoE) are likely to have a greater psychosocial burden from their condition, with a higher symptom burden score correlating positively with somatic symptom scores and negatively with quality of life (QoL).

Major finding: Compared with patients with longer disease duration (>12 months), those with shorter disease duration (6-12 months) had higher symptom burden (P = .03), somatic symptom (P < .01), and trait anxiety (P < .01) scores. Furthermore, a higher symptom burden was significantly associated with increased somatic symptoms (adjusted β [aβ] 0.34; 95% CI 0.23-0.45) and decreased QoL (aβ −0.42; 95% CI −0.59 to −0.25).

Study details: Findings are from a cross-sectional study including 87 pediatric patients with EoE, of whom 71 patients had longer disease duration.

Disclosures: This study was supported by a grant from the University of California San Diego (USCD) Academic Senate and US National Institutes of Health K24 and partially supported by the UCSD Altman Clinical and Translational Research Institute (ACTRI). The authors declared no conflicts of interest.

Source: Jensen ET, Chaiboonma K, Ayala O, Proia A, Aceves SS. Sleep, anxiety, somatization, quality of life, and resilience in pediatric patients with eosinophilic esophagitis. Clin Transl Gastroenterol. 2024 (Jan 11). Doi: 10.14309/ctg.0000000000000672  Source

Key clinical point: Treatment with dupilumab led to histologic remission and clinical benefits in patients with eosinophilic esophagitis (EoE) as early as within 12 weeks.

Major finding: The median composite symptom score reduced from 5.5 to 0 (P = .000488) and the median peak eosinophil counts decreased from 44.5 eosinophils/high‐power field (eos/hpf) to 2 eos/hpf (P = .000977) in patients who received dupilumab for 0-12 weeks. However, there were no significant differences in changes in median composite symptom score (P = .1350) and peak eosinophil count (P = .0746) among patients who received dupilumab between 0-12, 12-24, and >24 weeks.

Study details: This retrospective study included 79 patients with EoE who received dupilumab for a median period of 22.7 weeks, and of whom 12 patients received dupilumab for 0-12 weeks.

Disclosures: This study did not receive any specific funding. The corresponding author J Leung declared serving as a consultant for several sources.

Source: Sia T, Miller A, Bacchus L, et al. Dupilumab improves clinical and histologic features of eosinophilic esophagitis prior to 12 weeks of treatment. Clin Transl Allergy. 2024;14(1):e12333. Doi: 10.1002/clt2.12333 Source

Key clinical point: Treatment with dupilumab led to histologic remission and clinical benefits in patients with eosinophilic esophagitis (EoE) as early as within 12 weeks.

Major finding: The median composite symptom score reduced from 5.5 to 0 (P = .000488) and the median peak eosinophil counts decreased from 44.5 eosinophils/high‐power field (eos/hpf) to 2 eos/hpf (P = .000977) in patients who received dupilumab for 0-12 weeks. However, there were no significant differences in changes in median composite symptom score (P = .1350) and peak eosinophil count (P = .0746) among patients who received dupilumab between 0-12, 12-24, and >24 weeks.

Study details: This retrospective study included 79 patients with EoE who received dupilumab for a median period of 22.7 weeks, and of whom 12 patients received dupilumab for 0-12 weeks.

Disclosures: This study did not receive any specific funding. The corresponding author J Leung declared serving as a consultant for several sources.

Source: Sia T, Miller A, Bacchus L, et al. Dupilumab improves clinical and histologic features of eosinophilic esophagitis prior to 12 weeks of treatment. Clin Transl Allergy. 2024;14(1):e12333. Doi: 10.1002/clt2.12333 Source

Key clinical point: Treatment with dupilumab led to histologic remission and clinical benefits in patients with eosinophilic esophagitis (EoE) as early as within 12 weeks.

Major finding: The median composite symptom score reduced from 5.5 to 0 (P = .000488) and the median peak eosinophil counts decreased from 44.5 eosinophils/high‐power field (eos/hpf) to 2 eos/hpf (P = .000977) in patients who received dupilumab for 0-12 weeks. However, there were no significant differences in changes in median composite symptom score (P = .1350) and peak eosinophil count (P = .0746) among patients who received dupilumab between 0-12, 12-24, and >24 weeks.

Study details: This retrospective study included 79 patients with EoE who received dupilumab for a median period of 22.7 weeks, and of whom 12 patients received dupilumab for 0-12 weeks.

Disclosures: This study did not receive any specific funding. The corresponding author J Leung declared serving as a consultant for several sources.

Source: Sia T, Miller A, Bacchus L, et al. Dupilumab improves clinical and histologic features of eosinophilic esophagitis prior to 12 weeks of treatment. Clin Transl Allergy. 2024;14(1):e12333. Doi: 10.1002/clt2.12333 Source

Key clinical point: Patients diagnosed with both eosinophilic esophagitis (EoE) and inflammatory bowel diseases (IBD), like ulcerative colitis (UC) or Crohn’s disease (CD), are found to be more susceptible to immune-mediated comorbidities and IBD-related conditions but less susceptible to food bolus impaction.

Major finding: The risk for IBD-related complications (adjusted hazard ratio [aHR] > 1.1; P < .05) was higher, whereas the risk for food bolus impaction was lower (aHR 0.445; P  =  .0011), in patients with EoE and a concurrent diagnosis of IBD. The risk for immune-related comorbidities, such as celiac disease, IBD-related inflammatory conditions, eczema, and asthma, was also higher (P < .05) in patients with IBD who did vs did not have EoE.

Study details: Findings are from a retrospective population-based cohort study that included 174,755 patients with CD, 150,774 patients with UC, and 47,615 patients with EoE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Malik A, Liu BD, Zhu L, Kaelber D, Song G. A comprehensive global population-based analysis on the coexistence of eosinophilic esophagitis and inflammatory bowel disease. Dig Dis Sci. 2024 (Jan 13). doi: 10.1007/s10620-024-08283-2 Source

Key clinical point: Patients diagnosed with both eosinophilic esophagitis (EoE) and inflammatory bowel diseases (IBD), like ulcerative colitis (UC) or Crohn’s disease (CD), are found to be more susceptible to immune-mediated comorbidities and IBD-related conditions but less susceptible to food bolus impaction.

Major finding: The risk for IBD-related complications (adjusted hazard ratio [aHR] > 1.1; P < .05) was higher, whereas the risk for food bolus impaction was lower (aHR 0.445; P  =  .0011), in patients with EoE and a concurrent diagnosis of IBD. The risk for immune-related comorbidities, such as celiac disease, IBD-related inflammatory conditions, eczema, and asthma, was also higher (P < .05) in patients with IBD who did vs did not have EoE.

Study details: Findings are from a retrospective population-based cohort study that included 174,755 patients with CD, 150,774 patients with UC, and 47,615 patients with EoE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Malik A, Liu BD, Zhu L, Kaelber D, Song G. A comprehensive global population-based analysis on the coexistence of eosinophilic esophagitis and inflammatory bowel disease. Dig Dis Sci. 2024 (Jan 13). doi: 10.1007/s10620-024-08283-2 Source

Key clinical point: Patients diagnosed with both eosinophilic esophagitis (EoE) and inflammatory bowel diseases (IBD), like ulcerative colitis (UC) or Crohn’s disease (CD), are found to be more susceptible to immune-mediated comorbidities and IBD-related conditions but less susceptible to food bolus impaction.

Major finding: The risk for IBD-related complications (adjusted hazard ratio [aHR] > 1.1; P < .05) was higher, whereas the risk for food bolus impaction was lower (aHR 0.445; P  =  .0011), in patients with EoE and a concurrent diagnosis of IBD. The risk for immune-related comorbidities, such as celiac disease, IBD-related inflammatory conditions, eczema, and asthma, was also higher (P < .05) in patients with IBD who did vs did not have EoE.

Study details: Findings are from a retrospective population-based cohort study that included 174,755 patients with CD, 150,774 patients with UC, and 47,615 patients with EoE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Malik A, Liu BD, Zhu L, Kaelber D, Song G. A comprehensive global population-based analysis on the coexistence of eosinophilic esophagitis and inflammatory bowel disease. Dig Dis Sci. 2024 (Jan 13). doi: 10.1007/s10620-024-08283-2 Source

Key clinical point: A twice-daily moderate proton pump inhibitor (PPI) dose (20 mg omeprazole twice daily) induced greater histologic response rates in patients with eosinophilic esophagitis (EoE) than a once-daily moderate PPI dose (40 mg once daily), regardless of the total daily dosage.

Major finding: The rate of histologic remission significantly improved with twice-daily moderate vs once-daily moderate PPI dose (52.8% vs 10.0%; P < .0001). Compared with a standard PPI dose (20 mg omeprazole once daily), twice-daily moderate (adjusted odds ratio [aOR] 6.75; P = .0008) and high (40 mg omeprazole twice daily; aOR 12.8; P < .0001) PPI doses were associated with increased odds of histologic response.

Study details: This retrospective cohort study included 305 newly diagnosed patients with EoE who received standard, once-daily moderate, twice-daily moderate, or high PPI doses for more than 8 weeks.

Disclosures: This study did not disclose the source of any funding. Walter W. Chan declared serving on scientific advisory boards for various organizations, including Sanofi and Regeneron Pharmaceuticals.

Source: Muftah M, Goldin AH, Barshop K, et al. Twice daily PPI induces higher remission rate in eosinophilic esophagitis than once daily regimen regardless of total daily dose. Am J Gastroenterol. 2024 (Feb 5). doi: 10.14309/ajg.0000000000002712  Source

Key clinical point: A twice-daily moderate proton pump inhibitor (PPI) dose (20 mg omeprazole twice daily) induced greater histologic response rates in patients with eosinophilic esophagitis (EoE) than a once-daily moderate PPI dose (40 mg once daily), regardless of the total daily dosage.

Major finding: The rate of histologic remission significantly improved with twice-daily moderate vs once-daily moderate PPI dose (52.8% vs 10.0%; P < .0001). Compared with a standard PPI dose (20 mg omeprazole once daily), twice-daily moderate (adjusted odds ratio [aOR] 6.75; P = .0008) and high (40 mg omeprazole twice daily; aOR 12.8; P < .0001) PPI doses were associated with increased odds of histologic response.

Study details: This retrospective cohort study included 305 newly diagnosed patients with EoE who received standard, once-daily moderate, twice-daily moderate, or high PPI doses for more than 8 weeks.

Disclosures: This study did not disclose the source of any funding. Walter W. Chan declared serving on scientific advisory boards for various organizations, including Sanofi and Regeneron Pharmaceuticals.

Source: Muftah M, Goldin AH, Barshop K, et al. Twice daily PPI induces higher remission rate in eosinophilic esophagitis than once daily regimen regardless of total daily dose. Am J Gastroenterol. 2024 (Feb 5). doi: 10.14309/ajg.0000000000002712  Source

Key clinical point: A twice-daily moderate proton pump inhibitor (PPI) dose (20 mg omeprazole twice daily) induced greater histologic response rates in patients with eosinophilic esophagitis (EoE) than a once-daily moderate PPI dose (40 mg once daily), regardless of the total daily dosage.

Major finding: The rate of histologic remission significantly improved with twice-daily moderate vs once-daily moderate PPI dose (52.8% vs 10.0%; P < .0001). Compared with a standard PPI dose (20 mg omeprazole once daily), twice-daily moderate (adjusted odds ratio [aOR] 6.75; P = .0008) and high (40 mg omeprazole twice daily; aOR 12.8; P < .0001) PPI doses were associated with increased odds of histologic response.

Study details: This retrospective cohort study included 305 newly diagnosed patients with EoE who received standard, once-daily moderate, twice-daily moderate, or high PPI doses for more than 8 weeks.

Disclosures: This study did not disclose the source of any funding. Walter W. Chan declared serving on scientific advisory boards for various organizations, including Sanofi and Regeneron Pharmaceuticals.

Source: Muftah M, Goldin AH, Barshop K, et al. Twice daily PPI induces higher remission rate in eosinophilic esophagitis than once daily regimen regardless of total daily dose. Am J Gastroenterol. 2024 (Feb 5). doi: 10.14309/ajg.0000000000002712  Source

Key clinical point: Calcitonin gene-related peptide-antagonists, such as rimegepant and Ubrogepant, can be used for treating acute migraine due to their favorable efficacy and safety, whereas lasmiditan, despite showing promising efficacy, may increase the risk for adverse events (AE).

Major finding: Compared with other drugs, 100 mg ubrogepant showed the highest surface under the cumulative ranking curve (SUCRA) for providing quick pain freedom at 2 hours (0.79) and sustained pain freedom for over 24 hours (0.74), and 75 mg rimegepant showed the highest SUCRA for providing freedom from photophobia within 2 hours (0.96). Although both 100 mg and 200 mg lasmiditan provided relief from headache pain at 2 hours, they increased the risk for AE.

Study details: Findings are from a network meta-analysis of 18 studies including 22,429 patients with migraine who received lasmiditan, rimegepant, ubrogepant, and zavegepant.

Disclosures: This study was supported by the Fundamental Research Funds for the Central Universities, China. The authors declared no conflicts of interest.

Source: Deng X, Zhou L, Liang C et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25:16. doi: 10.1186/s10194-024-01723-4 Source

Key clinical point: Calcitonin gene-related peptide-antagonists, such as rimegepant and Ubrogepant, can be used for treating acute migraine due to their favorable efficacy and safety, whereas lasmiditan, despite showing promising efficacy, may increase the risk for adverse events (AE).

Major finding: Compared with other drugs, 100 mg ubrogepant showed the highest surface under the cumulative ranking curve (SUCRA) for providing quick pain freedom at 2 hours (0.79) and sustained pain freedom for over 24 hours (0.74), and 75 mg rimegepant showed the highest SUCRA for providing freedom from photophobia within 2 hours (0.96). Although both 100 mg and 200 mg lasmiditan provided relief from headache pain at 2 hours, they increased the risk for AE.

Study details: Findings are from a network meta-analysis of 18 studies including 22,429 patients with migraine who received lasmiditan, rimegepant, ubrogepant, and zavegepant.

Disclosures: This study was supported by the Fundamental Research Funds for the Central Universities, China. The authors declared no conflicts of interest.

Source: Deng X, Zhou L, Liang C et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25:16. doi: 10.1186/s10194-024-01723-4 Source

Key clinical point: Calcitonin gene-related peptide-antagonists, such as rimegepant and Ubrogepant, can be used for treating acute migraine due to their favorable efficacy and safety, whereas lasmiditan, despite showing promising efficacy, may increase the risk for adverse events (AE).

Major finding: Compared with other drugs, 100 mg ubrogepant showed the highest surface under the cumulative ranking curve (SUCRA) for providing quick pain freedom at 2 hours (0.79) and sustained pain freedom for over 24 hours (0.74), and 75 mg rimegepant showed the highest SUCRA for providing freedom from photophobia within 2 hours (0.96). Although both 100 mg and 200 mg lasmiditan provided relief from headache pain at 2 hours, they increased the risk for AE.

Study details: Findings are from a network meta-analysis of 18 studies including 22,429 patients with migraine who received lasmiditan, rimegepant, ubrogepant, and zavegepant.

Disclosures: This study was supported by the Fundamental Research Funds for the Central Universities, China. The authors declared no conflicts of interest.

Source: Deng X, Zhou L, Liang C et al. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. J Headache Pain. 2024;25:16. doi: 10.1186/s10194-024-01723-4 Source

Key clinical point: Habitual intake of caffeinated beverages may not increase headache frequency, duration, or intensity in patients with episodic migraine, contrary to popular belief.

Major finding: Compared with patients having episodic migraine who did not habitually consume caffeinated beverages, those who consumed 1-2 servings per day reported 0.3 (95% CI −2.0 to 2.5) more headache days per month, whereas those who consumed 3-4 servings per day reported 1.3 (95% CI −4.5 to 1.9) fewer headache days per month. Moreover, the headache duration and intensity did not differ across levels of caffeinated beverage intake.

Study details: This prospective cohort study evaluated the association between habitual caffeinated beverages intake and headache outcomes among 97 patients with episodic migraine (age ≥ 18 years).

Disclosures: This study was funded by US National Institute of Neurological Disorders and Stroke, the American Sleep Medicine Foundation, Harvard Catalyst—The Harvard Clinical and Translational Science Center. Suzanne M. Bertisch declared serving as a consultant for Idorsia and ResMed. The other authors declared no conflicts of interest.

Source: Mittleman MR, Mostofsky E, Vgontzas A, Bertisch SM. Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study. Headache. 2024 (Feb 6). doi: 10.1111/head.14673 Source

Key clinical point: Habitual intake of caffeinated beverages may not increase headache frequency, duration, or intensity in patients with episodic migraine, contrary to popular belief.

Major finding: Compared with patients having episodic migraine who did not habitually consume caffeinated beverages, those who consumed 1-2 servings per day reported 0.3 (95% CI −2.0 to 2.5) more headache days per month, whereas those who consumed 3-4 servings per day reported 1.3 (95% CI −4.5 to 1.9) fewer headache days per month. Moreover, the headache duration and intensity did not differ across levels of caffeinated beverage intake.

Study details: This prospective cohort study evaluated the association between habitual caffeinated beverages intake and headache outcomes among 97 patients with episodic migraine (age ≥ 18 years).

Disclosures: This study was funded by US National Institute of Neurological Disorders and Stroke, the American Sleep Medicine Foundation, Harvard Catalyst—The Harvard Clinical and Translational Science Center. Suzanne M. Bertisch declared serving as a consultant for Idorsia and ResMed. The other authors declared no conflicts of interest.

Source: Mittleman MR, Mostofsky E, Vgontzas A, Bertisch SM. Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study. Headache. 2024 (Feb 6). doi: 10.1111/head.14673 Source

Key clinical point: Habitual intake of caffeinated beverages may not increase headache frequency, duration, or intensity in patients with episodic migraine, contrary to popular belief.

Major finding: Compared with patients having episodic migraine who did not habitually consume caffeinated beverages, those who consumed 1-2 servings per day reported 0.3 (95% CI −2.0 to 2.5) more headache days per month, whereas those who consumed 3-4 servings per day reported 1.3 (95% CI −4.5 to 1.9) fewer headache days per month. Moreover, the headache duration and intensity did not differ across levels of caffeinated beverage intake.

Study details: This prospective cohort study evaluated the association between habitual caffeinated beverages intake and headache outcomes among 97 patients with episodic migraine (age ≥ 18 years).

Disclosures: This study was funded by US National Institute of Neurological Disorders and Stroke, the American Sleep Medicine Foundation, Harvard Catalyst—The Harvard Clinical and Translational Science Center. Suzanne M. Bertisch declared serving as a consultant for Idorsia and ResMed. The other authors declared no conflicts of interest.

Source: Mittleman MR, Mostofsky E, Vgontzas A, Bertisch SM. Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study. Headache. 2024 (Feb 6). doi: 10.1111/head.14673 Source